Business
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"\n \n \n \n Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n OAKVILLE, ON\n \n ,\n \n Nov. 2, 2021\n \n /CNW/ -\n \n Cardiol Therapeutics Inc.\n \n (NASDAQ: CRDL) (TSX: CRDL)\n \n (\"Cardiol\" or the \"Company\")\n \n , a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), has today filed a preliminary prospectus supplement (the \"\n \n Supplement\n \n \") to its short form base shelf prospectus dated\n \n August 3, 2021\n \n (the \"\n \n Base Prospectus\n \n \") in connection with a proposed public offering (the \"\n \n Offering\n \n \") of units (the \"Units\"). Each Unit will consist of one Class A common share of the Company (each, a \"\n \n Unit Share\n \n \") and one-half of one Class A common share purchase warrant of the Company (each, a \"\n \n Warrant\n \n \"). The Supplement was also filed with the U.S. Securities Exchange and Commission (the \"\n \n SEC\n \n \"), as part of a registration statement on Form-10, as amended, which was declared effective by the SEC on\n \n August 4, 2021\n \n , in accordance with the Multijurisdictional Disclosure System established between\n \n Canada\n \n and\n \n the United States\n \n .\n \n \n The Company intends to use the net proceeds from the Offering to advance the Company's research and clinical development programs, additional product development, and for general corporate purposes.\n \n \n Canaccord Genuity and Cantor Fitzgerald (the \"\n \n Underwriters\n \n \") are acting as joint bookrunners in connection with the Offering.\n \n \n The Offering is expected to be priced in the context of the market, with the final terms of the Offering to be determined at the time of pricing. There can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering. The closing of the Offering will be subject to customary closing conditions, includi...